Cisatracurium has neuromuscular blocking effects identical to those of atracurium, is more potent, and does not produce cardiovascular effects or increase plasma histamine concentrations.
A radioimmunoassay for the new angiotensin antagonist, saralasin , was developed and applied to pharmacologic studies in rats and hypertensive man. Specificity of the assay was established using naturally occurring angiotensins, potential saralasin metabolites, and other synthetic angiotensin analogues. Saralasin pharmacologic half-life of 3.9 min after intravenous administration to rats was similar to the biochemical half-life of 4.2 min. The pharmacologic half-life in high-renin hypertensive patients averaged 8.2 with a biochemical half-life of 3.2 min. These observations suggest that metabolites of saralasin do not accumulate in sufficient quantity in man or rat to interfere with the assay. The biochemical half-life of 3.2 min is consistent with infusion time of less than 20 min required to achieve a stable plasma concentration and pharmacologic activity of saralasin during constant saralasin infusion into hypertensive man. These studies provide a rational basis of future experimental design for saralasin and possibly other peptide analogues.Recent reports have indicated that substituted angiotensin II analogues can specifically antagonize the vascular, 2, 3, 10, 11,17,20,22,24,25,27,35,39 endocrine,s, 18 adrenergic potentiating,40 and central nervous system 27 , 35 effects of angiotensin II in animal systems. The advent of these compounds, in particular saralasin (l-Sar-8-Ala-angiotensin II), has provided a useful tool in the elucidation of the role of renin-angiotensin in blood pressure maintenance in acute and chronic unilateral renal hypertension in rats 24 , 27 Supported by grants from the Norwich Pharmacal co .• The Texas Heart Association, and the Merck Foundation.
A great deal of information has been obtained on the system of growth hormone and IGF-1 in development of osteoporosis. The imbalance of this system may be the cause of diseases of neonatal period as well as disease associated with aging. In old age, the synthesis of IGF-1 declines as well as the action of this peptide on tissues. The aim of this study is to find out the association between serum IGF-1 levels and bone mineral density. Sixty postmenopausal non osteoporotic women and sixty postmenopausal osteoporotic women were selected for this study. Out of 60 cases, 50 postmenopausal osteoporotic women completed the study. Bone mineral density (BMD) of postmenopausal women with symptom of osteoporosis was measured by ultrasonic bone densitometry (UBIS5000).Postmenopausal women with BMD results of T score ≤-2.5 were selected as cases and that of >-1 were selected as controls. Serum IGF-1 level was measured by ELISA method after removal of IGFBP from IGF-1. In this study, both base line BMD and serum IGF-1 level of the osteoporotic women were significantly lower than that of non osteoporotic women (p < 0.05). BMD and serum IGF-1 level in 3 months after calcitonin injection of osteoporotic women were significantly higher (p < 0.001) than that of baseline BMD and serum IGF-1 level. There was positive correlation between baseline serum IGF-1 and BMD level in postmenopausal osteoporotic women (r = 0.470, p = 0.001) as well as in control (r = 0.288, p= 0.025). It is hoped that this study will serve as ground for further study in the related fields, and thus, as part for the development of applications in the management of postmenopausal osteoporotic women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.